Lupin Reports Near 300% Profit Growth Coupled With Launches
The Company Expects To Maintain US Sales Above $200m Per Quarter
The Indian generics manufacturer has reported a nearly 300% year-on-year growth in profits in Q3, as it starts to see the impact of its Spiriva generic’s launch in the US.
